233 related articles for article (PubMed ID: 27354472)
1. Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation.
Wang Y; Liu H; Diao L; Potter A; Zhang J; Qiao Y; Wang J; Proia DA; Tailor R; Komaki R; Lin SH
Clin Cancer Res; 2016 Dec; 22(23):5876-5886. PubMed ID: 27354472
[TBL] [Abstract][Full Text] [Related]
2. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.
Shimamura T; Perera SA; Foley KP; Sang J; Rodig SJ; Inoue T; Chen L; Li D; Carretero J; Li YC; Sinha P; Carey CD; Borgman CL; Jimenez JP; Meyerson M; Ying W; Barsoum J; Wong KK; Shapiro GI
Clin Cancer Res; 2012 Sep; 18(18):4973-85. PubMed ID: 22806877
[TBL] [Abstract][Full Text] [Related]
3. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.
Acquaviva J; Smith DL; Sang J; Friedland JC; He S; Sequeira M; Zhang C; Wada Y; Proia DA
Mol Cancer Ther; 2012 Dec; 11(12):2633-43. PubMed ID: 23012248
[TBL] [Abstract][Full Text] [Related]
4. The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.
He S; Smith DL; Sequeira M; Sang J; Bates RC; Proia DA
Invest New Drugs; 2014 Aug; 32(4):577-86. PubMed ID: 24682747
[TBL] [Abstract][Full Text] [Related]
5. Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
Proia DA; Zhang C; Sequeira M; Jimenez JP; He S; Spector N; Shapiro GI; Tolaney S; Nagai M; Acquaviva J; Smith DL; Sang J; Bates RC; El-Hariry I
Clin Cancer Res; 2014 Jan; 20(2):413-24. PubMed ID: 24173541
[TBL] [Abstract][Full Text] [Related]
6. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.
Proia DA; Sang J; He S; Smith DL; Sequeira M; Zhang C; Liu Y; Ye S; Zhou D; Blackman RK; Foley KP; Koya K; Wada Y
Invest New Drugs; 2012 Dec; 30(6):2201-9. PubMed ID: 22227828
[TBL] [Abstract][Full Text] [Related]
7. Radioresistant human lung adenocarcinoma cells that survived multiple fractions of ionizing radiation are sensitive to HSP90 inhibition.
Gomez-Casal R; Epperly MW; Wang H; Proia DA; Greenberger JS; Levina V
Oncotarget; 2015 Dec; 6(42):44306-22. PubMed ID: 26517240
[TBL] [Abstract][Full Text] [Related]
8. Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer.
Liu H; Lu J; Hua Y; Zhang P; Liang Z; Ruan L; Lian C; Shi H; Chen K; Tu Z
Cell Death Dis; 2015 Jan; 6(1):e1595. PubMed ID: 25590805
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer.
Nagaraju GP; Zakka KM; Landry JC; Shaib WL; Lesinski GB; El-Rayes BF
Int J Cancer; 2019 Sep; 145(6):1529-1537. PubMed ID: 30801702
[TBL] [Abstract][Full Text] [Related]
10. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
[TBL] [Abstract][Full Text] [Related]
11. HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.
Lai CH; Park KS; Lee DH; Alberobello AT; Raffeld M; Pierobon M; Pin E; Petricoin Iii EF; Wang Y; Giaccone G
Oncogene; 2014 Oct; 33(40):4867-76. PubMed ID: 24166505
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation.
Patel K; Wen J; Magliocca K; Muller S; Liu Y; Chen ZG; Saba N; Diaz R
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1015-22. PubMed ID: 25205430
[TBL] [Abstract][Full Text] [Related]
13. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
14. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.
Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA
Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781
[TBL] [Abstract][Full Text] [Related]
15. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
Ying W; Du Z; Sun L; Foley KP; Proia DA; Blackman RK; Zhou D; Inoue T; Tatsuta N; Sang J; Ye S; Acquaviva J; Ogawa LS; Wada Y; Barsoum J; Koya K
Mol Cancer Ther; 2012 Feb; 11(2):475-84. PubMed ID: 22144665
[TBL] [Abstract][Full Text] [Related]
16. Ganetespib radiosensitization for liver cancer therapy.
Chettiar ST; Malek R; Annadanam A; Nugent KM; Kato Y; Wang H; Cades JA; Taparra K; Belcaid Z; Ballew M; Manmiller S; Proia D; Lim M; Anders RA; Herman JM; Tran PT
Cancer Biol Ther; 2016 Apr; 17(4):457-66. PubMed ID: 26980196
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models.
Lin SF; Lin JD; Hsueh C; Chou TC; Yeh CN; Chen MH; Wong RJ
Oncotarget; 2017 Jun; 8(25):41294-41304. PubMed ID: 28476040
[TBL] [Abstract][Full Text] [Related]
18. Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors.
Hashida S; Yamamoto H; Shien K; Ohtsuka T; Suzawa K; Maki Y; Furukawa M; Soh J; Asano H; Tsukuda K; Miyoshi S; Kanazawa S; Toyooka S
Oncol Rep; 2015 Mar; 33(3):1499-504. PubMed ID: 25607753
[TBL] [Abstract][Full Text] [Related]
19. Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in
Chatterjee S; Huang EH; Christie I; Kurland BF; Burns TF
Mol Cancer Ther; 2017 May; 16(5):793-804. PubMed ID: 28167505
[TBL] [Abstract][Full Text] [Related]
20. FGFR Inhibition Enhances Sensitivity to Radiation in Non-Small Cell Lung Cancer.
SenthilKumar G; Fisher MM; Skiba JH; Miller MC; Brennan SR; Kaushik S; Bradley ST; Longhurst CA; Buehler D; Nickel KP; Iyer G; Kimple RJ; Baschnagel AM
Mol Cancer Ther; 2020 Jun; 19(6):1255-1265. PubMed ID: 32371583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
